MKI67 and neoplasm: Neo-adjuvant therapy (HR 2.51, 95% CI: 1.91–3.30, P <  0.001), tumor > 2.0 cm (HR 1.54, 95% CI: 1.26–1.88, P <  0.001), positive ALN (HR 1.58, 95% CI: 1.29–1.93, P <  0.001), grade III (HR 1.44, 95% CI: 1.15–1.81), and Ki-67 ≥ 14% (HR 1.49, 95% CI: 1.21–1.85, P <  0.001) were associated with worse DFS in multivariable analysis, while PR ≥ 20% (HR 0.82, 95% CI: 0.67–1.00, P = 0.050) and endocrine therapy (HR 0.52, 95% CI: 0.37–0.73, P <  0.001) were associated with significantly better DFS (Table 3).